
Oncology NEWS International
- Oncology NEWS International Vol 16 No 4
- Volume 16
- Issue 4
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
GlaxoSmithKline Submits BLA for Cervarix HPV Vaccine
PHILADELPHIA, PennsylvaniaGlaxoSmithKline has submitted to the FDA a Biologics License Application (BLA) for Cervarix (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine. The vaccine is formulated with a proprietary adjuvant system called AS04 containing aluminum hydroxide and monophosphoryl lipid A. The submission includes data from clinical trials in almost 30,000 females age 10 to 55 reflecting an ethnically diverse population, the company said.
Articles in this issue
about 19 years ago
Curcumin Evaluated for the Treatment of Pancreatic Cancerabout 19 years ago
Tykerb Approved for Metastatic HER2+ Breast Cancerabout 19 years ago
Drug for BPH May Also Reduce the Risk of Prostate Cancerabout 19 years ago
Phase III Trial of Prostvac-VF Is Launchedabout 19 years ago
Electronic System Reminds Patients to Schedule Examsabout 19 years ago
Phase II Trial of Panzem for Renal Cell Carcinoma Initiatedabout 19 years ago
Chemotherapy May Enrich Tumorigenic Cells in Breast Caabout 19 years ago
Watchful Waiting Management for Prostate Ca a Hard SellNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
















































